Potensi Bakteriofag D29 sebagai Pendekatan Inovasi Pengobatan Molekuler terhadap Mutasi TB di Indonesia : Sistematik Review

Bayu Mangkurat; Deivan Pradana Putra

doi:10.53416/stmj.v5i2.352

Authors

Bayu Mangkurat (Top) Portfolio and function Coordinated ministries and agencies Organization Structure Minister References Coordinating Ministry for Maritime Affairs and Investment
Deivan Pradana Putra

DOI:

https://doi.org/10.53416/stmj.v5i2.352

Abstract

Maraknya kasus tuberkulosis (TB) di Indonesia menjadi tantangan besar bagi berbagai pihak sebagai akibat dari peningkatan kasus mutasi resistensi obat Mycobacterium tuberculosis (MDR-TB, XDR-TB, dan XXDR-TB). Resistensi ini disebabkan oleh mutasi Mycobacterium tuberculosis (M.tb) yang mengahambat efektivitas terapi pengobatan konvensional dengan menggunakan antibiotik. Bakteriofag D29 ini dianggap mampu menjadi agen terapi potensial karena kemampuan spesifiknya dalam melisiskan dan mengahancurkan dinding sel M.tb melalui siklus litik, tanpa mempengaruhi flora normal atau jaringan inang. Peninjauan literatur inovasi berbasis molekuler melibatkan bakteriofag D29 menawarkan potensi dalam pendekatan terapi pengobatan baru TB resisten. Bakteriofag D29 memiliki profil keamanan yang baik berdasarkan hasil uji pra-klinis, meskipun masih diperlukan uji klinis untuk memastikan keamanannya pada manusia. Inovasi implementasi bakteriofag D29 pada manusia dapat menjadi langkah strategis terapi molekuler TB di Indonesia dalam menghadapi beban resistensi yang terus meningkat.

References

Allué-Guardia, A., García, J. I., & Torrelles, J. B. (2021a). Evolution of Drug-Resistant Mycobacterium tuberculosis Strains and Their Adaptation to the Human Lung Environment. In Frontiers in Microbiology (Vol. 12). Frontiers Media S.A. https://doi.org/10.3389/fmicb.2021.612675

Allué-Guardia, A., Saranathan, R., Chan, J., & Torrelles, J. B. (2021b). Mycobacteriophages as potential therapeutic agents against drug-resistant tuberculosis. In International Journal of Molecular Sciences (Vol. 22, Issue 2, pp. 1–28). MDPI AG. https://doi.org/10.3390/ijms22020735

Bu, Q., Qiang, R., Fang, L., Peng, X., Zhang, H., & Cheng, H. (2023). Global trends in the incidence rates of MDR and XDR tuberculosis: Findings from the global burden of disease study 2019. Frontiers in Pharmacology, 14. https://doi.org/10.3389/fphar.2023.1156249

Chowdhury, K., Ahmad, R., Sinha, S., Dutta, S., & Haque, M. (2023). Multidrug-Resistant TB (MDR-TB) and Extensively Drug-Resistant TB (XDR-TB) Among Children: Where We Stand Now. Cureus. https://doi.org/10.7759/cureus.35154

Jacobs-Sera, D., Marinelli, L. J., Bowman, C., Broussard, G. W., Bustamante, C. G., Boyle, M. M., ... & Hatfull, G. F. (2012). On the nature of mycobacteriophage diversity and host preference. Virology, 434(2), 187-201.

Jeyasankar, S., Kalapala, Y. C., Sharma, P. R., & Agarwal, R. (2024). Antibacterial efficacy of mycobacteriophages against virulent Mycobacterium tuberculosis. BMC microbiology, 24(1), 320.

Lestari, B. W., Nijman, G., Larasmanah, A., Soeroto, A. Y., Santoso, P., Alisjahbana, B., Chaidir, L., Andriyoko, B., van Crevel, R., & Hill, P. C. (2024). Management of drug-resistant tuberculosis in Indonesia: a four-year cascade of care analysis. The Lancet Regional Health - Southeast Asia, 22. https://doi.org/10.1016/j.lansea.2023.100294

Mangkurat B., Rahmiati F., Nurwaesari N., Susanto A.B., Susanto A.H., Pangestuti R., Puspita M., and Meinita M.D.R., 2024. A Mini-Review: Metabolites of Kappaphycus alvarezii. STMJ 4 (2): 50-56

Mangkurat B., Susanto A.B., Susanto A.H., Pangestuti R., Puspita M., and Meinita M.D.R., 2025. Investigasi Genetika Budidaya Rumput Laut Di Wakatobi, Sulawesi Tenggara. (HAKI ID: 000860873)

Pohane, A. A., Joshi, H., & Jain, V. (2014). Molecular dissection of phage endolysin: an interdomain interaction confers host specificity in Lysin A of Mycobacterium phage D29. Journal of biological chemistry, 289(17), 12085-12095.

Rahayu, S. R., Susilastuti, M. S., Saefurrohim, M. Z., Azam, M., Indrawati, F., Supriyono, M., & Muflikhah, Z. (2023). Lost to Follow-Up among Tuberculosis Patients during the Public-Private Mix Era in Rural Area of Indonesia. Ethiopian journal of health sciences, 33(1).

Sengupta, S., Bhawsinghka, N., Shaw, R., Patra, M. M., & Gupta, S. K. D. (2022). Mycobacteriophage D29 induced association of Mycobacterial RNA polymerase with ancillary factors leads to increased transcriptional activity. Microbiology (United Kingdom), 168(3), 1–14. https://doi.org/10.1099/mic.0.001158

Singh, A. K., Gangakhedkar, R., Thakur, H. S., Raman, S. K., Patil, S. A., & Jain, V. (2023). Mycobacteriophage D29 Lysin B exhibits promising anti-mycobacterial activity against drug-resistant Mycobacterium tuberculosis. Microbiology Spectrum, 11(6), e04597-22.

Soedarsono, S., Mertaniasih, N. M., Kusmiati, T., Permatasari, A., Juliasih, N. N., Hadi, C., & Alfian, I. N. (2021). Determinant factors for loss to follow-up in drug-resistant tuberculosis patients: the importance of psycho-social and economic aspects. BMC Pulmonary Medicine, 21, 1-8.

Hossain, M. L., Hammer, K., Lim, L. Y., Hettiarachchi, D., & Locher, C. (2022). Optimisation of an agar overlay assay for the assessment of the antimicrobial activity of topically applied semi-solid antiseptic products including honey-based formulations. Journal of Microbiological Methods, 202, 106596.

Taneja, N. K., & Tyagi, J. S. (2007). Resazurin reduction assays for screening of anti-tubercular compounds against dormant and actively growing Mycobacterium tuberculosis, Mycobacterium bovis BCG and Mycobacterium smegmatis. Journal of antimicrobial chemotherapy, 60(2), 288-293.

World Health Organization. Global Tuberculosis Report 2020. Geneva: WHO; 2020.

Waste, D. O. Middlebrook 7H9 Broth. Technical Sheet. 2 pp. https://www.liofilchem.net/login/pd/ts/610214_TS.pdf

Yang, F., Labani-Motlagh, A., Bohorquez, J. A., Moreira, J. D., Ansari, D., Patel, S., & Yi, G. (2024). Bacteriophage therapy for the treatment of Mycobacterium tuberculosis infections in humanized mice. Communications Biology, 7(1), 294.